姐妹中出现的意外的阿霉素介导的心脏毒性：组胺N-甲基转移酶基因多态性的可能作用
Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.
作者信息
Sachidanandam Kamakshi, Gayle Arlene A, Robins H Ian, Kolesar Jill M
机构信息
University of Wisconsin School of Pharmacy, USA.
出版信息
J Oncol Pharm Pract. 2013 Sep;19(3):269-72. doi: 10.1177/1078155212461022. Epub 2012 Nov 15.
Abstract
The anthracycline anticancer agent doxorubicin has long been recognized to induce a dose-limiting cardiotoxicity and may be associated with genes relevant to doxorubicin disposition. Recent reports suggest a role for a number of single nucleotide polymorphisms in anthracycline cardiotoxicity in children. We describe two adult sisters with anthracycline cardiotoxicity that developed after a relatively low dose of doxorubicin. One sister carried the variant genotype for histamine N-ethyl transferase (HNMT, rs17583889) while the other was heterozygous, suggesting a similar role for these genotypes in adults with anthracycline cardiotoxicity. Although this requires further study, these genotypes may be important in the clinical dosing, or use of the liposomal formulation of doxorubicin.
摘要
蒽环类抗癌药物阿霉素长期以来被认为会引起剂量限制性心脏毒性，并且可能与阿霉素代谢相关基因有关。最近的报告表明，一些单核苷酸多态性在儿童蒽环类心脏毒性中起作用。我们描述了两名成年姐妹，她们在接受相对低剂量的阿霉素后出现了蒽环类心脏毒性。其中一名姐妹携带组胺N-乙基转移酶（HNMT，rs17583889）的变异基因型，而另一名是杂合子，这表明这些基因型在成年蒽环类心脏毒性患者中可能起类似作用。尽管这需要进一步研究，但这些基因型在阿霉素临床给药或脂质体制剂的使用中可能很重要。
相似文献
1
Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.姐妹中出现的意外的阿霉素介导的心脏毒性：组胺N-甲基转移酶基因多态性的可能作用
J Oncol Pharm Pract. 2013 Sep;19(3):269-72. doi: 10.1177/1078155212461022. Epub 2012 Nov 15.
2
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.有氧运动对乳腺癌患者蒽环类药物所致心脏毒性的调节作用：当前证据及潜在机制
Circulation. 2011 Aug 2;124(5):642-50. doi: 10.1161/CIRCULATIONAHA.111.021774.
3
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.ABCC5和NOS3基因多态性影响儿童急性淋巴细胞白血病幸存者的阿霉素心脏毒性。
Pharmacogenomics J. 2016 Nov;16(6):530-535. doi: 10.1038/tpj.2015.63. Epub 2015 Sep 8.
4
Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.基于非聚乙二醇化脂质体阿霉素方案与基于表柔比星方案治疗乳腺癌的心脏毒性：LITE（脂质体阿霉素-研究性化疗-组织多普勒成像评估）随机试点研究
Int J Cardiol. 2013 Aug 10;167(3):1055-7. doi: 10.1016/j.ijcard.2012.10.079. Epub 2012 Nov 20.
5
Genotyping the risk of anthracycline-induced cardiotoxicity.对蒽环类药物引起心脏毒性的风险进行基因分型。
Cardiovasc Toxicol. 2007;7(2):129-34. doi: 10.1007/s12012-007-0024-2.
6
Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.老年人中的阿霉素心脏毒性：旧药物与新机遇
J Clin Oncol. 2008 Jul 1;26(19):3122-4. doi: 10.1200/JCO.2008.16.5274.
7
Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.醛酮和羰基还原酶基因中的单核苷酸多态性与柔红霉素化疗后急性心脏毒性无关。
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2118-20. doi: 10.1158/1055-9965.EPI-12-1037. Epub 2012 Sep 20.
8
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005006. doi: 10.1002/14651858.CD005006.pub2.
9
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2010 May 12;2010(5):CD005006. doi: 10.1002/14651858.CD005006.pub4.
10
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2010 Mar 17(3):CD005006. doi: 10.1002/14651858.CD005006.pub3.
引用本文的文献
1
Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.化疗所致心脏毒性的潜在基因关联研究：一项系统评价与荟萃分析
Front Cardiovasc Med. 2021 Jun 4;8:651269. doi: 10.3389/fcvm.2021.651269. eCollection 2021.
2
Brazilian Cardio-oncology Guideline - 2020.《巴西心脏肿瘤学指南 - 2020》
Arq Bras Cardiol. 2020 Nov;115(5):1006-1043. doi: 10.36660/abc.20201006.
3
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.干预化疗引起的心脏毒性的可能易感性基因。
Oxid Med Cell Longev. 2020 Oct 13;2020:4894625. doi: 10.1155/2020/4894625. eCollection 2020.
4
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.候选基因关联研究蒽环类药物诱导的心脏毒性：系统评价和荟萃分析。
Sci Rep. 2017 Feb 27;7(1):39. doi: 10.1038/s41598-017-00075-1.
5
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.蒽环类药物所致充血性心力衰竭的全基因组关联研究
Clin Cancer Res. 2017 Jan 1;23(1):43-51. doi: 10.1158/1078-0432.CCR-16-0908. Epub 2016 Dec 19.
6
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.关于基因检测以降低蒽环类药物所致心脏毒性发生率的建议。
Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
7
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.RARG基因中的一个编码变异赋予儿童癌症患者对蒽环类药物诱导的心脏毒性的易感性。
Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.
8
Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.心肌病早期病变的影像学研究：阿霉素诱导模型。
Int J Cardiovasc Imaging. 2013 Oct;29(7):1459-76. doi: 10.1007/s10554-013-0248-0. Epub 2013 Jun 7.
本文引用的文献
1
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.蒽环类药物相关的儿童期癌症后心肌病：羰基还原酶基因多态性的作用——来自儿童肿瘤学组的报告。
J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.
2
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.儿童蒽环类药物诱导性心脏毒性的药物基因组学预测。
J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6.
3
Anthracycline cardiotoxicity: from bench to bedside.蒽环类药物心脏毒性：从 bench 到 bedside。
注：bench 直译为“实验台”，bedside 直译为“床边”，这里意译为从基础研究到临床应用。
J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401.
4
Genotyping the risk of anthracycline-induced cardiotoxicity.对蒽环类药物引起心脏毒性的风险进行基因分型。
Cardiovasc Toxicol. 2007;7(2):129-34. doi: 10.1007/s12012-007-0024-2.
5
Adriamycin-induced oxidative mitochondrial cardiotoxicity.阿霉素诱导的氧化性线粒体心脏毒性。
Cell Biol Toxicol. 2007 Jan;23(1):15-25. doi: 10.1007/s10565-006-0140-y. Epub 2006 Sep 28.
6
The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart.ATP结合盒转运体及其在药物处置中的作用：对心脏的特别关注。
Pharmacol Rev. 2006 Jun;58(2):244-58. doi: 10.1124/pr.58.2.7.
7
Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase.人羰基还原酶对13-脱氧柔红霉素和柔红霉醇蒽醌的还原作用
Cardiovasc Toxicol. 2005 Fall;5(4):365-76. doi: 10.1385/ct:5:4:365.
8
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.烟酰胺腺嘌呤二核苷酸磷酸（NAD(P)H）氧化酶和多药耐药蛋白基因多态性与阿霉素诱导的心脏毒性有关。
Circulation. 2005 Dec 13;112(24):3754-62. doi: 10.1161/CIRCULATIONAHA.105.576850. Epub 2005 Dec 5.
9
10
Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.羰基还原酶1无效等位基因小鼠对阿霉素诱导的心脏毒性的保护作用。
Cancer Res. 2003 Oct 15;63(20):6602-6.
Zotero 插件